Mumbai (Maharashtra) [India], August 9: Cupid Limited (BSE – 530843, NSE – CUPID) is rapidly scaling its In-Vitro Diagnostic (IVD) test kits business, driven by strong domestic demand, a growing international footprint and a clear expansion strategy.
Key Highlights:
• Diverse Product Portfolio: 15 IVD rapid test kits currently in production, including HIV, Syphilis, Pregnancy, and Hepatitis B; 3 new kits under development.
• Regulatory Certifications in Progress:
o CE Certification for 4 key products expected soon in 2025.
o WHO Prequalification for Malaria Test Kit targeted by mid-2026.
o Application for Malaria Pf Ag WHO prequalification by Q3 2026.
• Government Tender Eligibility: Eligible for all Central and State Government tenders after completing 3 years of production at the Maharashtra facility.
• Retail & GeM Demand: Available at chemist stores and labs nationwide. Supplying 120+ ESIC hospitals via the Government e-Marketplace with regular order flows.
• Modern Manufacturing Facility:
o Current Capacity: 1 lakh kits/day.
o Upcoming Capacity: 4 lakh kits/day by end-2026 through phased automation.
o New Machines: Fully automated pouching machine (installed); second machine (Q2 FY26); reel-to-reel dip & dry system (Q3 FY26).
• Approvals & Quality Compliance:
o Product approvals from CDSCO, ICMR, NIMR, NIB, RGCB.
o Certified for ISO 13485:2016, ISO 9001:2015, and ISO 14001:2015.
• Global Market Expansion: Country registrations completed and business initiated in Tanzania, Ghana, Liberia, Bangladesh, Philippines, Sierra Leone, Bhutan, Nepal and Uganda.
Cupid is well-positioned to expand its IVD business through certification-led global entry, rising government and retail demand and automated production scaling. With strong momentum and strategic investments, the IVD segment is expected to become a key growth engine for the company.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.